期刊文献+

加校正因子的主成分自身对照法测定阿托伐他汀钙中杂质D的含量 被引量:5

Determination of the Content of Impurity D in Atorvastatin Calcium with the Corretion Factor
原文传递
导出
摘要 目的建立加校正因子的主成分自身对照法测定阿托伐他汀钙中杂质D的含量。方法采用HPLC,色谱柱为Agilent ZORBAX SB-C8(4.6 mm×250 mm,5μm)和Agilent Eclipse XDB-C8(4.6 mm×250 mm,5μm),流动相A为乙腈-四氢呋喃-柠檬酸盐溶液(3.9 g·L?1一水合柠檬酸溶液用氨水调节p H值至5.0)(21∶12∶67);流动相B为乙腈-四氢呋喃-柠檬酸盐溶液(3.9 g·L?1一水合柠檬酸溶液用氨水调节p H值至5.0)(61∶12∶27),梯度洗脱;检测波长:244 nm;流速为1.5 m L·min?1,柱温35℃;进样量:20μL。通过测定阿托伐他汀钙和杂质D的线性方程,以斜率计算杂质D相对于阿托伐他汀钙的校正因子。结果测得杂质D相对于阿托伐他汀钙的保留时间为1.96,相对校正因子为0.94,采用外标法和加校正因子的主成分自身对照法分别测定3批阿托伐他汀钙中杂质D的含量,2组检测结果无差异。结论用加校正因子的主成分自身对照法测定阿托伐他汀钙中杂质D的含量,方法可行。 OBJECTIVE To establish a method using the correction factor to determine the content of the impurity D in atorvastatin calcium. METHODS An optimal HPLC method was set up to determine the concentration of impurity D in atorvastatin calcium. The column was Agilent ZORBAX SB-C8(4.6 mm×250 mm, 5 μm) and Agilent Eclipse XDB-C8(4.6 mm×250 mm, 5 μm). The mobile phase A consisted of acetonitrile-tetrahydrofuran-buffer(3.9 g·L-1 citric acid solution adjust with ammonium hydroxide to a p H of 5.0)(21∶12∶67), mobile phase B consisted of acetonitrile-tetrahydrofuran-buffer(3.9 g·L-1 citric acid solution adjust with ammonium hydroxide to a p H of 5.0)(61∶12∶27), gradient elute. The detection wavelength was 244 nm and the flow was 1.5 m L·min-1. The column temperature was 35 ℃ and the injection volume was 20 μL. Then, used the slope of linear equation to determine the correction factor between impurity D and atorvastatin calcium. RESULTS The relative retention time between impurity D and atorvastatin calcium was 1.96, and the relative correction factor was 0.94. And there was no difference between the results determined by the external standard method and the self contrast and correction factor method. CONCLUSION The method using the correction factor between substance being examined and impurity to determine the content of impurity D in atorvastatin calcium is available.
出处 《中国现代应用药学》 CAS CSCD 2015年第12期1476-1480,共5页 Chinese Journal of Modern Applied Pharmacy
关键词 阿托伐他汀钙 杂质D 校正因子 atorvastatin calcium impurity D the correction factor
  • 相关文献

参考文献7

  • 1邹阳春.他汀类药物的临床应用及其前景展望[J].心血管病学进展,2001,22(5):261-264. 被引量:28
  • 2王正林,应俊,林圣超,姚振宇,邓卫平,杜文婷.阿托伐他汀钙的合成研究进展[J].中国现代应用药学,2011,28(5):423-428. 被引量:10
  • 3LUO Q H,WU H C.Effect of atorvastatin on hypercholes- terolemia [J].Chin Hosp Pharm J,2008,28(4):293-295.
  • 4EP 8.0 [S].2013:1598-1600.
  • 5USP 37-NF32 [S].2014:1863-1867.
  • 6JP XVI [S] 2011:404-405.
  • 7Vukkum P,Moses Bsbu J,Muralikrishna R.Stress degrada- tion behavior of atorvastatin calcium and development of a suitable stability-indicating LC method for the determination of atorvastatin,its related impurities,and its degradation products [J].Sci Pharm,2013(81):93-114.

二级参考文献40

  • 1徐颂.阿托伐他汀钙合成路线[J].中国新药杂志,2006,15(22):1913-1917. 被引量:11
  • 2CHENBS SULH.Advances in the research of statins .中国药房,2005,16(7):545-546.
  • 3MOTHANA B, BOYD R J. A density functional theory study of the mechanism of the Paal-Knorr pyrrole synthesis [J]. Theochem, 2007, 811(1/3): 97-107.
  • 4BAUMANN K L, BUTLER D E, DEERING C F, et al. The convergent synthesis of CI-981, an optically active, highly potent, tissue selective inhibitor of HMG-CoA reductase [J] Tetrahedron Lett, 1992, 33(17): 2283-2284.
  • 5WOO P W K, HARTMAN J, HUANG Y, et al. Atorvastatin, an HMG-CoA reductase inhibitor and efficient lipid-regulation agent [J]. J Labelled Cpd Radiopharm, 1999, 42(2): 121-127.
  • 6BUTLER D E, LE T V, MILLAR A, et al. Process for the synthesis of (5R)-1,1-dimethyl ethyl-6-cyano-5-hydroxy-3- oxo-hexanoate: US, 5155251 [P]. 1992-11-03.
  • 7BROWER P L, BUTLER D E, ROTH B D, et al. The synthesis of (4R-cis) -l, l dimethylethyl-6-cyanomethyl-2, 2-dimethyl-1,3-dioxane-4-acetate, a key intermediate for the preparation of CI-981, a highly potent, tissue selective inhibitor of HMG-CoA reductase [J]. Tetrahedron Lett, 1992, 33(17): 2279-2282.
  • 8BUTLER D E, LE T V, NANNINGA T N, et al. Process for trans-6-[2-(substituted-Pyrrol-1-yl) alkyl] pyran-2-one inhibitors of cholesterol synthesis: US, 5298627 [P]. 1994-29-03.
  • 9PATEL D J, KUMAR R, DWIVEDI S D. Process for the preparation of atorvastatin calcium: WO, 2007096751A1 [P]. 2007-30-08.
  • 10BUTLER D E, DEERING C F, MILLAR A, et al. Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one nhibitors of cholesterol synthesis: US, 5280126 [P]. 1994-18-01.

共引文献36

同被引文献72

引证文献5

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部